Description
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Catalog No.
DHD37502
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
Research Grade Biosimilar
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P20138
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字： Lintuzumab;DHD37502;gp67, SIGLEC3;
武汉佰乐博生物（Biolab Reagents）由五位毕业于华中科技大学，华中农业大学，武汉大学等知名高校，且具有二十年工作经验的生命科学领域顶级研究者创立于2021年，凭借丰富的产品开发经验，利用全球领先的技术平台，引进和整合全球高品质的蛋白、抗体和试剂盒产品。目前，佰乐博生物作为法国AntibodySystem在亚洲的独家总代理，提供近30,000种生命科学试剂，核心产品涵盖蛋白、抗体和试剂盒，旨在为科研工作者提供专业、全面、可靠的试剂支持，推动生命科学研究的深入发展。